Tharimmune, Inc.
Biotechnology Research
Bridgewater, NJ 423 followers
Biotech company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases.
About us
Tharimmune, Inc. (Nasdaq: THAR) is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or "uncontrollable itching" in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting unique epitopes with novel mechanisms of action against well-known, validated targets in multiple solid tumors. Tharimmune has a license agreement with OmniAb, Inc. to access the company's antibody discovery technology platform against specified targets. For more information please visit: www.tharimmune.com
- Website
-
www.tharimmune.com
External link for Tharimmune, Inc.
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Bridgewater, NJ
- Type
- Public Company
Locations
-
Primary
Get directions
1200 Route 22
East Suite 2000
Bridgewater, NJ 08807, US
Employees at Tharimmune, Inc.
-
Thomas P. Hess, CPA, MBA
Chief Financial Officer
-
Kelly Anderson, CPA
Founder and CEO - CXO Executive Solutions, LLC Experienced public company board member
-
Leonard Mazur
Chief Executive Officer at Citius Pharmaceuticals, Inc. (formerly Leonard Meron Biosciences, Inc.)
-
Randy M.
Chief Executive Officer at Tharimmune, Inc.